Gilead Sciences (GILD) Surges As Bristol-Myers' (BMY) Hep C Drug Has Major Setback

Article Stock Quotes (2) Comments (0)

Gilead Sciences Inc. (Nasdaq: GILD) is having a strong day Thursday at the expense of Bristol-Myers Squibb (NYSE: BMY), which pulled a Hep C pipeline drug due to safety issues.

Bristol-Myers suspended an ongoing Phase II study of BMS-986094, a nucleotide polymerase (NS5B) inhibitor in development for the treatment of hepatitis C, on the emergence of a "serious safety issue" which appears to be a heart attack that occurred in a patient on a 200-mg daily dose.

Gilead Sciences has its own Hep C treatment and now has the upper hand.

Based on this one event, analysts at Barclays upgraded Gilead to 'Overweight' and downgraded Bristol-Myers Squibb to 'Equal Weight.'

Shares of Gilead are up 9.3 percent, while Bristol-Myers Squibb is down 7 percent.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• EMA Approves MAA for Gilead's (GILD) Sofosbuvir
• UPDATE: Cubist Pharmaceuticals (CBST) Spikes to Session Highs
• UPDATE: Move Inc (MOVE) Higher, Citron Says Long on Twitter

Create E-mail Alert Related Categories

FDA, Trader Talk

Related Entities

Barclays

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?